Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Metamark Appoints Cornelius J. Merlini Chief Commercial Officer

Published: Thursday, October 03, 2013
Last Updated: Thursday, October 03, 2013
Bookmark and Share
General Manager of recently acquired national uropathology laboratory to lead ProMark™ Commercialization.

Metamark Genetics, Inc. has announced that Cornelius J. Merlini, former general manager of HealthTronics Laboratory Solutions (HLS), has been appointed Metamark's Senior Vice President and Chief Commercial Officer.

In August 2013, Metamark acquired HLS, a national uropathology laboratory, from Endo Health Solutions, Inc. Mr. Merlini will report to Metamark President and Chief Executive Officer, Shawn M. Marcell, and will join the company's senior leadership team.

"We are pleased that Cornelius has joined Metamark. His exceptional leadership, commercial acumen, and track record bringing paradigm-changing products to market have produced transformational business growth," said Mr. Marcell.

Mr. Marcell continued, "Cornelius already is an established leader of Metamark's newly-acquired uropathology business, where he assembled a talented, dedicated team - including a specialized national field sales force. This commercial team nicely complements Metamark's innovative research and development efforts, and will accelerate the launch of ProMark™, our novel prostate cancer prognostic test."

"Metamark's strong science engine fits perfectly with its new commercial and operational machine," said Mr. Merlini. "ProMark™ could redefine the management of early stage prostate cancer and become a standard test sought by patients and ordered by urologists when making well-informed treatment decisions. It is exciting to join a company that could change the way prostate cancer is treated."

Mr. Merlini has over twenty-five years of life science experience across a wide array of functions and businesses.

Prior to HealthTronics Lab Solutions, Mr. Merlini was SVP, Commercial Operations at Cord Blood Registry, a market leader in cord blood stem cell banking.

He spent ten years with increasing marketing, management and franchise leadership responsibilities at Johnson & Johnson, where he served most recently as Worldwide Vice-President of the cardiovascular franchise for Johnson & Johnson's biopharmaceutical business.

Earlier, Mr. Merlini gained successful sales and sales leadership experience with Marion Laboratories (now Sanofi-Aventis).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Metamark Genetics Partners with Definiens on Tissue-Based Cancer Diagnostics
Partnership forged to tackle tumor heterogeneity.
Monday, July 04, 2011
Scientific News
"Gene Fusion" Drives Childhood Brain Cancers
Study co-led by Penn scientists highlights potential targets for future cancer therapies.
Head Injury Patients Develop Brain Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
New Way to Identify Brain Tumor Aggressiveness
Looking at a brain tumor’s epigenetic signature may help guide therapy.
OncoCyte, The Wistar Institute Enter Global Licensing Agreement
Exclusive rights to commercialize biomarker assay follows years of positive collaboration on lung cancer diagnostic test.
Easier Diagnosis for Fungal Infection of the Lungs
A new clinical imaging method developed in collaboration with a University of Exeter academic may enable doctors to tackle one of the main killers of patients with weakened immune systems sooner and more effectively.
Antibiotic Susceptibility Testing
A team of biologists and biomedical researchers at UC San Diego has developed a new method to determine if bacteria are susceptible to antibiotics within a few hours, an advance that could slow the appearance of drug resistance and allow doctors to more rapidly identify the appropriate treatment for patients with life threatening bacterial infections.
Mitochondrial Troublemakers Unmasked in Lupus
Drivers of autoimmune disease inflammation discovered in the traps of pathogen-capturing white blood cells.
DNA Analysis in the Fast Lane
Rice bioengineers' method should lead to better database of thermal behaviors.
‘Simple Rules’ Calculate Ovarian Cancer Risk
Scientists have formulated a system that uses ultrasound images to accurately work out the likelihood of an ovarian growth being cancerous.
Finding the Needle in a Microbial Haystack
After developing a novel investigational technology called PathoChip that can rapidly identify elusive microorganisms, a team of Penn Medicine researchers recently succeeded for the first time in identifying a pathogen in a patient sample, demonstrating the proof of principle that this technology can be used to identify pathogens in human disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!